Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer von Hoste, G., Punie, K., Wildiers, H., Beuselinck, B., Lefever, I., Van Nieuwenhuysen, E., Han, S. N., Berteloot, P., Concin, N., Salihi, R., Vergote, I., Neven, P.

Volltext

Features of durable response and treatment efficacy for capecitabine monotherapy in advanced breast cancer: real-world evidence from a large single-centre cohort von Thijssen, S., Wildiers, H., Punie, K., Beuselinck, B., Clement, P., Remmerie, C., Berteloot, P., Han, S., Van Nieuwenhuysen, E., Van Gorp, T., Vergote, I., Smeets, A., Nevelsteen, I., Floris, G., Weltens, C., Menten, J., Janssen, H., Laenen, A., Neven, P.

Volltext

Breast cancer subtype and survival by parity and time since last birth von De Mulder, H., Laenen, A., Wildiers, H., Punie, K., Poppe, A., Remmerie, C., Lefrère, H., Nevelsteen, I., Smeets, A., Van Nieuwenhuysen, E., Han, S., Van Limbergen, E., Floris, G., Vergote, I., Neven, P.

Volltext

Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D von Timmerman, S., Van Rompuy, A.S., Van Gorp, T., Vanden Bempt, I., Brems, H., Van Nieuwenhuysen, E., Han, S.N., Neven, P., Victoor, J., Laenen, A., Vergote, I.

Volltext

HIPEC: HOPE or HYPE in the fight against advanced ovarian cancer? von Fotopoulou, C., Sehouli, J., Mahner, S., Harter, P., Van Nieuwenhuysen, E., Gonzalez-Martin, A., Vergote, I., Chiva, L., Du Bois, A.

Volltext

Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium von Nagle, C M, Dixon, S C, Jensen, A, Kjaer, S K, Modugno, F, deFazio, A, Fereday, S, Hung, J, Johnatty, S E, Fasching, P A, Beckmann, M W, Lambrechts, D, Vergote, I, Van Nieuwenhuysen, E, Lambrechts, S, Risch, H A, Rossing, M A, Doherty, J A, Wicklund, K G, Chang-Claude, J, Goodman, M T, Ness, R B, Moysich, K, Heitz, F, du Bois, A, Harter, P, Schwaab, I, Matsuo, K, Hosono, S, Goode, E L, Vierkant, R A, Larson, M C, Fridley, B L, Høgdall, C, Schildkraut, J M, Weber, R P, Cramer, D W, Terry, K L, Bandera, E V, Paddock, L, Rodriguez-Rodriguez, L, Wentzensen, N, Yang, H P, Brinton, L A, Lissowska, J, Høgdall, E, Lundvall, L, Whittemore, A, McGuire, V, Sieh, W, Rothstein, J, Sutphen, R, Anton-Culver, H, Ziogas, A, Pearce, C L, Wu, A H, Webb, P M

Volltext

Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies von Vergote, I.B., Lund, B., Peen, U., Umajuridze, Z., Mau-Sorensen, M., Kranich, A., Van Nieuwenhuysen, E., Haslund, C., Nottrup, T., Han, S.N., Concin, N., Unger, T.J., Chai, Y., Au, N., Rashal, T., Joshi, A., Crochiere, M., Landesman, Y., Shah, J., Shacham, S., Kauffman, M., Mirza, M.R.

Volltext

Randomized phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer von Vergote, I., Van Nieuwenhuysen, E., Casado, A., Laenen, A., Lorusso, D., Braicu, E.I., Guerra-Alia, E., Zola, P., Wimberger, P., Debruyne, P.R., Falcó, E., Ferrero, A., Muallem, M.Z., Kerger, J., García-Martinez, E., Pignata, S., Sehouli, J., Van Gorp, T., Gennigens, C., Rubio, M.J.

Volltext

Robot-assisted surgery for women with endometrial cancer: Surgical and oncologic outcomes within a Belgium gynaecological oncology group cohort von Kakkos, A., Ver Eecke, C., Ongaro, S., Traen, K., Peeters, F., Van Trappen, Ph, Laenen, A., Despierre, E., Van Nieuwenhuysen, E., Vergote, I., Goffin, F.

Volltext

Curative effect of second curettage for treatment of gestational trophoblastic disease - Results of the Belgian registry for gestational trophoblastic disease von Vandewal, A., Delbecque, K., Van Rompuy, A.S., Noel, J.-Ch, Marbaix, E., Delvenne, P., Nisolle, M., Van Nieuwenhuysen, E., Kridelka, F., Vergote, I., Goffin, F., Han, S.N.

Volltext

Expression III: patients’ expectations and preferences regarding physician–patient relationship and clinical management—results of the international NOGGO/ENGOT-ov4-GCIG study in 1... von Oskay-Özcelik, G., Alavi, S., Richter, R., Keller, M., Chekerov, R., Cecere, S.C., Cormio, G., Joly, F., Kurtz, J.E., du Bois, A., Maciejewski, M., Jedryka, M., Vergote, I., Van Nieuwenhuysen, E., Casado, A., Mendiola, C., Achimas-Cadariu, P., Vlad, C., Reimer, D., Zeimet, A.G., Friedlander, M., Sehouli, J.

Volltext

Ovarian cancer in children and adolescents: a rare disease that needs more attention von Baert, T, Storme, N, Van Nieuwenhuysen, E, Uyttebroeck, A, Van Damme, N, Vergote, I, Coosemans, A

Volltext

Preoperative c-reactive protein and thrombocyte count as potential markers for longterm survival in ovarian cancer von Braicu, E.I., Sehouli, J., Richter, R., Vergote, I.B., Concin, N., van Nieuwenhuysen, E., Achimas, P., Berger, A., Fetica, B., Mahner, S., Glajzer, J., Papadia, A., Woelber, L., Gasparri, M.L., Vanderstichele, A., Benedetti Panici, P., Mueller, M., Ruscito, I., Zimmer, J., Woopen, H.

Volltext

OC10.06: Imaging in gynecological disease: clinical and ultrasound features of immature teratomas of the ovary von Landolfo, C., Froyman, W., Testa, A.C., Czekierdowski, A., Guerriero, S., Coosemans, A., Franchi, D., Van Holsbeke, C., Van Calster, B., Verbakel, J., Van Nieuwenhuysen, E., Vergote, I., Timmerman, D., Valentin, L.

Volltext

2777 Lavage of the uterine cavity for early and differential diagnosis of serous ovarian cancer von Maritschnegg, E, Wang, Y, Pecha, N.M, Horvat, R, Van Nieuwenhuysen, E, Vergote, I, Kinde, I, Papadopoulos, N, Diaz, L.A, Kinzler, K.W, Vogelstein, B, Zeillinger, R, Speiser, P

Volltext

615TiP NIRVANA-1: A multicentre randomized study comparing carboplatin-paclitaxel (CP) followed by niraparib (nira) to CP–bevacizumab (bev) followed by nira-bev in patients with FI... von Freyer, G., Gonzalez Martin, A.J., Raspagliesi, F., Peron, J., Van Nieuwenhuysen, E., Hasegawa, K., Lim, M-C., Ray-Coquard, I.L.

Volltext

CCNE1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study von Nelson, Gregg S., Ghatage, Prafull, Lee, Cheng‐Han, Bolithon, Adelyn, Popovic, Gordana, Leung, Betty, Millstein, Joshua, Anglesio, Michael S., Ataseven, Beyhan, Barlow, Ellen, Beckmann, Matthias W., Bisinotto, Christiani, Boros, Jessica, Brand, Alison H., Brooks‐Wilson, Angela, Carney, Michael E., Casablanca, Yovanni, Cazorla‐Jiménez, Alicia, Conrads, Thomas P., Cook, Linda S., Coulson, Penny, Crowe, Philip, Darcy, Kathleen M., El‐Bahrawy, Mona A., Elishaev, Esther, Erber, Ramona, Farrell, Rhonda, Fischer, Anna, García, María J., Gayther, Simon A., Gentry‐Maharaj, Aleksandra, Gilks, C. Blake, Grube, Marcel, Harrington, Shariska Petersen, Harter, Philipp, Hartmann, Arndt, Hecht, Jonathan L., Hein, Alexander, Heitz, Florian, Hendley, Joy, Hernandez, Brenda Y., Polo, Susanna Hernando, Heublein, Sabine, Hirasawa, Akira, Høgdall, Estrid, Høgdall, Claus K., Horlings, Hugo M., Huntsman, David G., Jewell, Andrea, Kaufmann, Scott H., Kennedy, Catherine J., Khabele, Dineo, Kommoss, Felix K. F., Kruitwagen, Roy F. P. M., Lambrechts, Diether, Le, Nhu D., Lener, Marcin, Lester, Jenny, Leung, Yee, Linder, Anna, Loverix, Liselore, Lubiński, Jan, Maxwell, G. Larry, Neuhausen, Susan L., Olawaiye, Alexander, Orsulic, Sandra, Pike, Malcolm C., Mohan, Ganendra Raj, Rodríguez‐Antona, Cristina, Ruebner, Matthias, Sasamoto, Naoko, Schildkraut, Joellen M., Schoemaker, Minouk J., Shah, Mitul, Sharma, Raghwa, Sonke, Gabe S., Stewart, Colin J. R., Sundfeldt, Karin, Talhouk, Aline, Tan, Adeline, Taylor, Sarah E., Traficante, Nadia, Nieuwenhuysen, Els, Vergote, Ignace, Wilkens, Lynne R., Winham, Stacey J., Wu, Anna H., Candido dos Reis, Francisco J., DeFazio, Anna, Fasching, Peter A., Goode, Ellen L., Gronwald, Jacek, Kommoss, Stefan, Menon, Usha, Sinn, Hans‐Peter, Staebler, Annette, Brenton, James D., Bowtell, David D., Pharoah, Paul D. P., Köbel, Martin

Volltext

732P Durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib as a first-line treatment for endometrial cancer (EC): Progression-free survival (PFS) by clinical f... von Blank, S.V., McCollum, M., Anderson, C., Pennington, K., Salinas, E., Richardson, D.L., Slomovitz, B.M., Kim, B-G., Liu, J., Mori, M., Guette, P.L. Ramos, Joseph de Pádua, C., Martinez-Garcia, J., Papadimitriou, C., Grisan, K., Póka, R.L., Kowgier, M., Del Rosario, P.M.D., Van Nieuwenhuysen, E., Westin, S.

Volltext

288MO InnovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or met... von Fujiwara, K., Slomovitz, B.M., Gonzalez Martin, A., Kalbacher, E., Bagameri, A., Ghamande, S., Lee, J-Y., Banerjee, S., Maluf, F.C., Lorusso, D., Yonemori, K., van Nieuwenhuysen, E., Manso Sanchez, L.M., Woelber, L., Westermann, A.M., Covens, A., Whalley, E., Teng, M.S.L., Soumaoro, I., Vergote, I.B.

Volltext

LBA9 innovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or meta... von Vergote, I.B., Gonzalez Martin, A., Fujiwara, K., Kalbacher, E., Bagameri, A., Ghamande, S., Lee, J-Y., Banerjee, S., Maluf, F.C., Lorusso, D., Yonemori, K., Van Nieuwenhuysen, E., Manso Sanchez, L.M., Woelber, L., Westermann, A.M., Covens, A., Whalley, E., Teng, M.S.L., Soumaoro, I., Slomovitz, B.M.

Volltext